Skip to main content

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

Publication ,  Journal Article
Jamnagerwalla, J; Howard, LE; Allott, EH; Vidal, AC; Moreira, DM; Castro-Santamaria, R; Andriole, GL; Freeman, MR; Freedland, SJ
Published in: Prostate cancer and prostatic diseases
June 2018

Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. These potential biases may affect PSA-driven biopsy rates and subsequent prostate cancer detection in men with high serum cholesterol. Our objective was to test the association between serum cholesterol and prostate cancer risk in men receiving PSA independent, study-mandated prostate biopsies.We conducted a post hoc analysis of data from 4974 non-statin users in REDUCE, a randomized trial in men with elevated PSA and a negative baseline biopsy. Men underwent 2- and 4-year trial-mandated prostate biopsies. Associations between baseline serum levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and prostate cancer risk, overall and by Gleason grade (<7 vs. ≥7), were examined using multivariable logistic regression.High total serum cholesterol was associated with an increased risk of high-grade prostate cancer diagnosis (OR per 10 mg/dL 1.05; 95% CI 1.00-1.09; p = 0.048), but cholesterol was unrelated to either overall or low-grade prostate cancer risk (p-values >0.185). There was no association between serum LDL and overall, low- or high-grade prostate cancer risk (p-values >0.137). In contrast, elevated serum HDL was associated with increased risk of both overall (OR per 10 mg/dL 1.08; 95% CI 1.01-1.16; p = 0.033) and high-grade prostate cancer (OR per 10 mg/dL 1.14; 95% CI 1.01-1.28; p = 0.034).In REDUCE, where all men received PSA independent, trial-mandated biopsies thus ensuring complete prostate cancer ascertainment, high total serum cholesterol and high HDL were associated with increased risk of high-grade prostate cancer, supporting a cholesterol-prostate cancer link.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate cancer and prostatic diseases

DOI

EISSN

1476-5608

ISSN

1365-7852

Publication Date

June 2018

Volume

21

Issue

2

Start / End Page

252 / 259

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Risk Factors
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jamnagerwalla, J., Howard, L. E., Allott, E. H., Vidal, A. C., Moreira, D. M., Castro-Santamaria, R., … Freedland, S. J. (2018). Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 21(2), 252–259. https://doi.org/10.1038/s41391-017-0030-9
Jamnagerwalla, Juzar, Lauren E. Howard, Emma H. Allott, Adriana C. Vidal, Daniel M. Moreira, Ramiro Castro-Santamaria, Gerald L. Andriole, Michael R. Freeman, and Stephen J. Freedland. “Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate Cancer and Prostatic Diseases 21, no. 2 (June 2018): 252–59. https://doi.org/10.1038/s41391-017-0030-9.
Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate cancer and prostatic diseases. 2018 Jun;21(2):252–9.
Jamnagerwalla, Juzar, et al. “Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate Cancer and Prostatic Diseases, vol. 21, no. 2, June 2018, pp. 252–59. Epmc, doi:10.1038/s41391-017-0030-9.
Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR, Freedland SJ. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate cancer and prostatic diseases. 2018 Jun;21(2):252–259.

Published In

Prostate cancer and prostatic diseases

DOI

EISSN

1476-5608

ISSN

1365-7852

Publication Date

June 2018

Volume

21

Issue

2

Start / End Page

252 / 259

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Risk Factors
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Humans